Search

Displaying results 8221 - 8230 of 10000 in total
  1. Drug

    RAG-17

    go.drugbank.com/drugs/DB18503
    Investigational

    RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase (SOD).

  2. Drug

    CEB-01

    go.drugbank.com/drugs/DB18505
    Investigational

    CEB-01 is a biocompatible polymeric PLGA nanofiber membrane containing the active substance 7-ethyl-10-hydroxycamptothecin

  3. Drug

    IDUA-RTB

    go.drugbank.com/drugs/DB18612
    Experimental

    RTB-IDUA is a fusion protein of alpha-L-iduronidase (IDUA) and ricin transport subunit B (RTB).

  4. Drug

    DU125530

    go.drugbank.com/drugs/DB16040
    Investigational

    DU125530 is under investigation in clinical trial NCT01119430 (Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder).

    Categories: Heterocyclic Compounds, 1-Ring, Serotonin 5-HT1 Receptor Antagonists
  5. Drug

    Dynorphin

    go.drugbank.com/drugs/DB16146
    Investigational

    Dynorphin is under investigation in clinical trial NCT00000244 (Effects of Dynorphin 1-13 on Heroin Addiction - 1).

    Synonyms: Dynorphin a (1-17), Dynorphin a 1-17
  6. Drug

    GP2 peptide

    go.drugbank.com/drugs/DB16180
    Investigational

    GP2 peptide is under investigation in clinical trial NCT00524277 (Vaccine Therapy in Treating Patients With Breast Cancer).

    Synonyms: Gp-2 her2-derived, hla-a2+ restricted peptide
  7. Drug

    C-peptide

    go.drugbank.com/drugs/DB16187
    Investigational

    C-peptide is under investigation in clinical trial NCT00278980 (Effect of C-peptide on Diabetic Peripheral Neuropathy).

    Synonyms: C-peptide, Human c-peptide
  8. Drug

    Lonaprisan

    go.drugbank.com/drugs/DB16221
    Investigational

    Lonaprisan is under investigation in clinical trial NCT00555919 (ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer).

  9. Drug

    Osalmid

    go.drugbank.com/drugs/DB16273
    Investigational

    Osalmid is under investigation in clinical trial NCT03670173 (Safety and Efficacy Assessments of Osalmid in Multiple Myeloma).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    KB109

    go.drugbank.com/drugs/DB16531
    Experimental

    KB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.